EntryPoint Capital LLC Reduces Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

EntryPoint Capital LLC lowered its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 11.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,971 shares of the company’s stock after selling 1,833 shares during the period. EntryPoint Capital LLC’s holdings in Takeda Pharmaceutical were worth $185,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Crowley Wealth Management Inc. purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at approximately $52,000. LPL Financial LLC raised its holdings in Takeda Pharmaceutical by 1.9% in the fourth quarter. LPL Financial LLC now owns 186,652 shares of the company’s stock valued at $2,471,000 after acquiring an additional 3,564 shares in the last quarter. American Century Companies Inc. boosted its stake in Takeda Pharmaceutical by 6.0% during the 4th quarter. American Century Companies Inc. now owns 301,087 shares of the company’s stock valued at $3,986,000 after acquiring an additional 17,103 shares during the last quarter. Summit Global Investments grew its holdings in Takeda Pharmaceutical by 75.5% during the 4th quarter. Summit Global Investments now owns 729,200 shares of the company’s stock worth $9,655,000 after acquiring an additional 313,642 shares in the last quarter. Finally, Boston Partners bought a new stake in shares of Takeda Pharmaceutical in the 4th quarter worth about $915,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $15.06 on Friday. The firm has a market cap of $47.90 billion, a PE ratio of 37.64, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.31. The firm’s 50-day simple moving average is $14.16 and its 200-day simple moving average is $13.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.